Becton Dickinson reported Q1 2026 adjusted earnings of $2.91 per share, beating consensus of $2.81, with sales of $5.25 billion slightly above the $5.15 billion consensus. However, the company significantly lowered its fiscal 2026 adjusted earnings guidance to $12.35-$12.65 per share from $14.75-$15.05, citing transition year headwinds in China, vaccines, and Alaris. Multiple analysts cut price targets, with RBC reducing its forecast from $210 to $172, Wells Fargo from $184 to $157, and Piper Sandler from $205 to $170. BDX shares fell 17.44% to $171.23.

Software stocks extended their rebound with the iShares Expanded Tech-Software Sector ETF jumping over 3%, while the Nasdaq 100 climbed 1% and S&P 500 added 0.7%. Silver led commodities with a 6% rally to $82, while oil jumped 2% and gold rallied 2.5%. Notable gainers included AppLovin Corp surging 14%, Oracle rising 11%, and Palantir Technologies up 7%. Crypto markets lagged with Bitcoin slipping 0.4% to $70,000.

Waters Corporation reported Q4 2025 earnings that beat expectations with $932.36M in sales (7% growth) and $4.53 EPS versus consensus of $4.51. However, the stock fell 9.61% on Monday due to weaker-than-expected Q1 2026 guidance of $2.25-$2.35 EPS (vs. consensus $2.52) and conservative full-year 2026 outlook, despite management's optimism about momentum continuing into 2026.

Becton Dickinson reported Q1 2026 adjusted earnings of $2.91 per share, beating consensus of $2.81, with sales of $5.25 billion slightly above expectations. However, the company significantly lowered its fiscal 2026 adjusted earnings guidance from $14.75-$15.05 per share to $12.35-$12.65 per share, well below the consensus of $14.72. The guidance cut follows the company's spinoff and combination of its Biosciences and Diagnostic Solutions business with Waters Corporation.

The global chromatography market is projected to grow from USD 10.03 billion in 2025 to USD 13.69 billion by 2031 at a CAGR of 5.32%, driven by expanding R&D in pharma/biotech and strict food safety regulations. However, high capital costs limit adoption among smaller entities. Emerging trends include green chromatography and AI-powered method optimization.

Agilent Technologies delivered strong Q4 FY2025 results with $1.86B revenue (9.4% reported growth, 7.2% core growth) and $1.59 non-GAAP EPS, marking the sixth consecutive quarter of sequential core growth acceleration. The company's diversified portfolio spanning chromatography, mass spectrometry, and lab automation, combined with its high-margin CrossLab services business, provides structural resilience during industry downturns. Trading at 23.7x EV/EBITDA with a modest P/E premium to historical averages, Agilent's valuation reflects strong execution, pricing power, and efficient capital allocation through buybacks and strategic acquisitions like BioVectra.

William Blair initiated Outperform coverage on Waters Corporation following its merger with Becton Dickinson's Biosciences & Diagnostic Solutions business. The analyst sees greater synergy upside than initially priced in, with EPS accretion of ~$0.10 in 2026 rising to ~$2.70 by 2028. William Blair projects roughly 20% upside by year-end 2026 and believes the $345 million EBITDA synergy target is conservative based on comparable large M&A deals in life sciences.

The article highlights two investment opportunities in the pharmaceutical and medical device sectors that could benefit from AI-driven drug development: Becton Dickinson (BDX) and the BlackRock Health Sciences Fund (BME), both currently undervalued and offering attractive dividend yields.

Fenimore Asset Management completely sold its entire 243,780 shares of Waters Corporation, valued at $85.09 million, representing a full exit from the position during Q3 2025. The sale reflects a strategic portfolio shift amid challenging market conditions for laboratory instrumentation stocks.

Healthcare merger and acquisition activity rose 7% in Q3 2025, with 532 deals announced. Physician Medical Groups led with 130 deals, while total deal value reached $63.8 billion, a 111% increase from the previous quarter.

The global chromatography market in pharmaceuticals and biotechnology is projected to grow from $13.3 billion in 2025 to $19.8 billion by 2030, with an 8.4% CAGR, driven by rising biopharmaceutical innovations, regulatory standards, and demand for generics and biosimilars.

The global chromatography market is expected to grow from $12.3 billion in 2024 to $18.8 billion by 2031, with a 6.1% CAGR. Liquid chromatography dominates the market, with pharmaceutical and environmental testing industries driving growth, particularly in North America and Asia-Pacific regions.